Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A



Status:Completed
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:7 - 65
Updated:11/22/2017
Start Date:January 2006
End Date:June 2010

Use our guide to learn which trials are right for you!

Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A

The primary purpose of this randomized, two-arm parallel clinical study in 66 previously
treated patients with severe or moderately severe hemophilia A is to compare the rate of
bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose
determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6
hours; actual dose determined by Baxter utilizing an algorithm and the patient's
pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the
prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled
patients will be treated originally on demand for a period of 6 months and then they will be
randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of
12 months +/- 2 weeks.


Inclusion Criteria:

- The subject has severe or moderately severe hemophilia A as defined by a baseline
factor VIII level <= 2% of normal, as tested at screening

- The subject has a documented history of at least 150 exposure days to factor VIII
concentrates (either plasma-derived or recombinant)

- The subject is within 7 to 65 years of age

- The subject has a Karnofsky performance score > (greater than) 60

- The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a CD4
count >= 400 cells/mm³ (CD4 count determined at screening, if necessary)

- The subject has been on a documented on-demand treatment regimen for at least 12
months immediately prior to enrollment

- The subject has a documented history (e.g. in medical charts or dispensing
information, or signed investigator statement) of at least 8 joint hemorrhages in the
12 months immediately prior to enrollment

- The subject resides within the coverage area of the mobile compliance device; coverage
area will be determined at screening

- The subject or the subject's legally authorized representative has provided written
informed consent

Exclusion Criteria:

- The subject has a known hypersensitivity to factor VIII concentrates or mouse or
hamster proteins

- The subject has a history of factor VIII inhibitors with a titer >= 0.6 BU (by
Bethesda or Nijmegen assay) at any time prior to screening

- The subject has a detectable factor VIII inhibitor at screening, with a titer >= 0.4
BU (by Nijmegen Assay) in the central laboratory

- The subject has severe chronic liver disease as evidenced by, but not limited to, any
of the following: International Normalized Ratio (INR) > 1.4, hypoalbuminemia, portal
vein hypertension including presence of otherwise unexplained splenomegaly and history
of esophageal varices.

- The subject has been diagnosed with an inherited or acquired hemostatic defect other
than hemophilia A (e.g., qualitative platelet defect or von Willebrand's Disease)

- The subject has been treated during the last sixty (60) days prior to or is being
treated at screening/enrollment with an immunomodulating drug.

- The subject has participated in another investigational study within thirty (30) days
of enrollment

- The subject has previously participated in a clinical study with rAHF-PFM

- The subject's clinical condition may require a major surgery (defined as moderate to
critical risk and perioperative blood loss ≥ 500 mL) during the period of the
subject's participation in the study

- The subject is female of childbearing potential with a positive pregnancy test
We found this trial at
10
sites
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Hershey, PA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Vienna,
Click here to add this to my saved trials